아시아 태평양 생물학 시장 – 2030년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Asia Pacific Biologics Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 생물학 시장 – 2030년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jan 2023
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 207
  • 그림 수: 48
지금 구매 지금 구매

Asia Pacific Biologics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2030
Diagram 시장 규모(기준 연도)
 백만 달러
요구
Diagram 시장 규모(예측 연도)
 미국 달러 141,276.35
Diagram 연평균 성장률
 %
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
잠금 해제 요청

>아시아 태평양 생물학 시장, 종류별(종양괴사인자-A(TNF) 억제제, B세포 억제제, 인터루킨 억제제 , 선택적 공동자극 조절제(아바타셉트) 및 기타), 유형별(단일클론 항체(MAB), 치료용 단백질, 백신, 세포 기반 생물학 제제, 유전자 기반 생물학 제제 및 기타), 투여 경로(주사 및 주입), 응용 분야(종양학, 자가면역 질환, 당뇨병, 감염성 질환, 심혈관 질환, 안과 질환, 피부 질환 및 기타), 원료 물질(인간, 조류 세포 배양, 효모, 박테리아, 곤충 세포 배양, 형질전환 및 기타), 최종 사용자(병원, 전문 병원, 학계 및 연구 기관 및 기타), 유통 채널(직접 입찰, 소매 판매 및 제3자) 유통) 산업 동향 및 2030년 전망.

아시아 태평양 생물학 시장

아시아 태평양 생물학 시장 분석 및 통찰력

생물학적 제제는 생물체 또는 생물체의 일부 성분에서 생산된 약물입니다. 이러한 약물은 인간, 조류 세포 배양, 효모 , 박테리아, 곤충 세포 배양 등을 포함한 다양한 생물학적 출처에서 유래될 수 있습니다. 이러한 약물에는 치료용 단백질, 단일클론 항체, 백신이 포함됩니다. 이러한 약물은 암, 염증성 질환, 대사 질환, 심혈관 질환, 감염성 질환을 포함한 다양한 유형의 만성 질환을 치료하는 데 사용할 수 있습니다 .

아시아 태평양 생물학 시장

아시아 태평양 생물학 시장

아시아 태평양 생물학 시장은 2023년부터 2030년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2023년부터 2030년까지의 예측 기간 동안 11.5%의 CAGR로 성장하고 있으며 2030년까지 141,276.35백만 달러에 도달할 것으로 예상한다고 분석했습니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 해

2021 (2020-2016까지 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

분류별(종양괴사인자-A(TNF) 억제제, B세포 억제제, 인터루킨 억제제, 선택적 공동자극 조절제(아바타셉트) 및 기타), 유형별( 단일클론항체 (MAB), 치료용 단백질, 백신, 세포 기반 생물학 제제, 유전자 기반 생물학 제제 및 기타), 투여 경로(주사 및 주입), 적용 분야(종양학, 자가면역 질환, 당뇨병, 감염성 질환, 심혈관 질환, 안과 질환, 피부과 질환 및 기타), 원료 물질(인간, 조류 세포 배양, 효모, 박테리아, 곤충 세포 배양, 형질전환 및 기타), 최종 사용자(병원, 전문 클리닉, 학계 및 연구 기관 및 기타), 유통 채널(직접 입찰, 소매 판매 및 제3자 유통).

적용 국가

중국, 일본, 인도, 호주, 한국, 싱가포르, 말레이시아, 인도네시아, 태국, 필리핀, 베트남, 그리고 나머지 아시아 태평양 지역.

시장 참여자 포함

AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.

Market Definition

Biologics are the drugs produced from living organisms or some components of living organisms that have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced the demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proven to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.

The major factor that drives the market growth is the rise in the prevalence of chronic diseases such as diabetes and cancer in developing countries. Furthermore, rise in initiatives by governments and surge in research for new biologics drugs are some of the factors that boost the market growth. However, lack of awareness about healthcare in developing countries is a major factor that restrains the market growth. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for market expansion in the forecast period.

Asia-Pacific Biologics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

  • Rising prevalence of chronic diseases such as diabetes and cancers

Chronic diseases are one of the biggest healthcare concerns in the world, claiming an estimated 40 million lives every year, 8.5 million of whom reside in Asia. In Asia-Pacific, cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions are among the most common chronic diseases. This is primarily driven by aging populations and poor lifestyle choices such as the lack of physical activity and tobacco & alcohol consumption.

  • Changes in lifestyle

Lifestyle diseases share risk factors similar to prolonged exposure to three modifiable lifestyle behaviors, smoking, unhealthy diet, and physical inactivity, and result in the development of chronic diseases, specifically heart disease, stroke, diabetes, obesity, metabolic syndrome, Chronic Obstructive Pulmonary Disease (COPD), and some types of cancer.

  • Recent advancements in biologics

Delivery by injection is the most convenient method for biologics delivery. It is not always ideal. This is primarily because of the pharmacokinetics of biologics, which means they are rapidly cleared from systemic circulation.

Co-formulation of therapeutics is an emerging strategy that aims to capitalize on advances in therapeutic effects observed through the co-administration of biologics.

RESTRAINTS

  • Complex manufacturing process of biologics

Biologics drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as Critical Quality Attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The complexity of the manufacturing process leads to several defaults. Thus, the complex manufacturing process of biologics is acting as a major restraining factor for market growth.

  • Adverse side-effects of biologics

Like standard pharmaceuticals, biological treatments can cause adverse drug reactions. They can cause allergic reactions similar to the ways these drugs can. But they can also cause problems due to the way biologics interact with the immune system. They can also sometimes cause specific issues with various organ systems in the body.

Some of the side effects associated with biologics are:

  • Injection site reactions
  • Infusion reactions

Usually, these reactions are mild. However, sometimes they may be more severe such as hypersensitivity reactions, and require medical intervention.

Thus, adverse side effects of biologics treatment act as a restraint for market growth.

아시아 태평양 생물학 시장

OPPORTUNITIES

  • Rising healthcare expenditure

Across the globe, R&D activities are escalating owing to public health expenditure with economic performance. At the same time, the healthcare industry ranks second among all industries regarding R&D. Rising healthcare expenditure can result in better provision of R&D opportunities. That results in the anticipated upsurging demand for various cancer diagnostics.

  • Strategic initiatives by market players

An increase in the burden of various types of diseases such as cancers, diabetes, and cardiovascular diseases across Asia-Pacific, coupled with the rise in the geriatric population, has created more demand for biologics. The main aim is to improve health management in biologics for quality care with convenient application. Hence, major market players are focusing on fulfilling the demand for biologics and spending a noticeable amount on better products.

Thus, these strategic product launches, acquisitions, and mergers by major companies in the biologics market have opened up opportunities for companies in Asia. This strategy is allowing the companies to strengthen their footprints in the market.

  • Surge in healthcare expenditure

Healthcare expenditure has increased across Asia-Pacific region, as the disposable income of people across Asia is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare organizations to improve their treatment facilities for the usage of biologics.

  • Growing number of biopharmaceutical contract manufacturing companies in Asia

The biopharmaceutical contract manufacturing market is growing essentially due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia-Pacific. Increasing competition in the industry is likely to damage the market growth in the coming years. Additionally, robust advancements in R&D activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of biopharmaceutical contract manufacturing companies during the forecast period.

The growing number of biopharmaceutical contract manufacturing companies leads to the development of new products via rigorous research to treat various diseases. Thus, this acts as an opportunity for market growth.

CHALLENGE

  • Stringent regulatory policies

Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for the legal selling of medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins among others are of significant importance for treating various diseases. But their approval and marketing in multiple regions across Asia require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.

Thus, the above-mentioned stringent regulations and policies for approving the complicated nature of biologics act as a challenge to market growth.

Post-COVID-19 Impact on Asia-Pacific Biologics Market

The COVID-19 pandemic had somewhat negative impact on the biologics market. Due to the pandemic, new norms and regulations were imposed, such as social distancing and lockdown to prevent the spread of virus. As a result, people all over the world were forced to stay at home. This stay-at-home led to a decrease in the consumption of biologics, which further led to a decrease in the demand for biologics.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the quality of biologics existing in the market.

Recent Developments

Many product launches and agreements are also initiated by companies worldwide which are accelerating the market growth.

  • In November 2021, Biocon launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launch helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
  • In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch was developed in partnership with the Department of Biotechnology, Government of India.

Asia-Pacific Biologics Market Scope

Asia-Pacific biologics market is segmented into seven notable segments based on class, type, route of administration, application, source material, end user, and distribution channel.

By Class

  • Tumor Necrosis Factor-Α (TNF) Inhibitors
  • B-Cell Inhibitors
  • Interleukin Inhibitors
  • Selective Co-Stimulation Modulators (Abatacept)
  • Others

Based on class, the market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.

By Type

  • Monoclonal Antibodies (mABs)
  • Therapeutic Proteins
  • Vaccines
  • Cellular Based Biologics
  • Gene Based Biologics
  • Other

Based on type, the market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other.

By Route of Administration

  • Injection
  • Infusion

Based on route of administration, the market is segmented into injection, and infusion.

By Application

  • Oncology
  • Autoimmune Diseases
  • Diabetes
  • Infectious Diseases
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Dermatological Diseases
  • Others

Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.

By Source Material

  • Humans
  • Avian Cell Culture
  • Yeast
  • Bacteria
  • Insects Cell Culture
  • Transgenics
  • Others

Based on source material, the market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others.

By End User

  • Hospital
  • Specialty Clinics
  • Academics and Research Institutes
  • Others

최종 사용자를 기준으로 시장은 병원, 전문 클리닉, 학계 및 연구 기관, 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 소매 판매
  • 제3자 배포

유통 채널을 기준으로 시장은 직접 입찰, 소매 판매, 제3자 유통으로 구분됩니다.

아시아 태평양 생물학 시장

아시아 태평양 생물학 시장 지역 분석/통찰력

아시아 태평양 생물학 시장을 분석하고, 국가, 계열, 유형, 투여 경로, 응용 분야, 원료 물질, 최종 사용자 및 유통 채널을 기반으로 시장 규모 정보를 제공합니다.

2022년에는 아시아 태평양 지역이 당뇨병과 암과 같은 만성 질환의 유병률 증가로 인해 성장했습니다. 중국은 생물학의 최근 발전으로 인해 시장을 지배할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인과 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 아시아 태평양 생물학 시장 점유율 분석

아시아 태평양 생물학 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세 및 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

이 시장에서 활동하는 주요 기업으로는 AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. 등이 있습니다. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, YL Biologics 등이 있습니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of Asia-Pacific biologics market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. class LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET application COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
    1. Pestel's ANALYSIS
    2. Porter’s five forces
    3. Epidemiology
  5. Pipeline analysis
  6. Asia-Pacific Biologics Market: Laws and regulations
  7. market overview
    1. DRIVERS
      1. INCREASE IN PREVALENCE OF CHRONIC DISEASES SUCH AS DIABETES AND CANCERS
      2. CHANGES IN LIFESTYLE
      3. RECENT ADVANCEMENTS IN BIOLOGICS
    2. RESTRAINTS
      1. COMPLEX MANUFACTURING PROCESS OF BIOLOGICS
      2. ADVERSE SIDE-EFFECTS OF BIOLOGICS
    3. OPPORTUNITIES
      1. RISE IN HEALTHCARE EXPENSES
      2. STRATEGIC INITIATIVES BY MARKET PLAYERS
      3. surge in healthcare expenditure
      4. GROWING NUMBER OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING COMPANIES IN ASIA
    4. CHALLENGE
      1. STRINGENT REGULATORY POLICIES
  8. COVID-19 IMPACT ON Asia-Pacific biologics Market
    1. impact on price
    2. impact on demand
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISIONS of Government and MANUFACTURERS
    5. Conclusion
  9. Asia-Pacific biologics market, BY class
    1. overview
    2. Tumor Necrosis Factor-Α (TNF) Inhibitors
      1. Adalimumab
      2. Certolizumab
      3. Etanercept
      4. Infliximab
      5. Others
    3. B-Cell Inhibitors
      1. Belimumab
      2. Rituximab
      3. others
    4. Interleukin Inhibitors
      1. Anakinra
      2. Canakinumab
      3. Ixekizumab
      4. Secukinumab
      5. Tocilizumab
      6. Ustekinumab
      7. Others
    5. Selective Co-Stimulation Modulators (Abatacept)
    6. Others
  10. Asia-Pacific biologics market, BY route of administration
    1. overview
    2. INjECTION
    3. infusion
  11. Asia-Pacific biologics market, BY drug classification
    1. overview
    2. Branded Drugs
    3. generic drugs
  12. Asia-Pacific biologics market, BY source material
    1. overview
    2. Bacteria
    3. Avian Cell Culture
    4. Humans Cell Lines
    5. Yeast
    6. Insects Cell Culture
    7. Transgenics
  13. asia-pacific biologics MARKET, By type
    1. overview
    2. Monoclonal Antibodies (Mabs)
      1. Anti-Cancer Mabs
      2. Immunological Mabs
      3. Anti-Infective Monoclonal Antibodies (Mabs)
      4. Cardiovascular And Cerebrovascular Mabs
      5. Neuropharmacological Mabs
      6. Others Mabs
    3. Therapeutic Proteins
      1. Metabolic Disorders Therapeutic Proteins
      2. Cancer Therapeutic Proteins
      3. Cardiovascular Therapeutic Proteins
      4. Immunological Therapeutic Proteins
      5. Others Therapeutic Proteins
    4. Vaccines
      1. Anti-Infective Vaccines
      2. Autoimmunity Vaccines
      3. others
    5. cellular bassed biologics
    6. gene based biologics
    7. others
  14. asia-pacific biologics MARKET, By application
    1. overview
    2. oncology
      1. Breast Cancer
      2. Lung Cancer
      3. Leukemia
      4. Ovarian Cancer
      5. Non-Hodgkin Lymphoma
      6. Prostate Cancer
      7. Colorectal Cancer
      8. Others
    3. Infectious Diseases
    4. Autoimmune Diseases
      1. Rheumatoid Arthritis
      2. Systemic Lupus Erythematous
      3. Systemic Sclerosis
      4. Crohn’s Disease
      5. Sjogren's Syndrome
      6. Multiple Sclerosis
      7. Pernicious Anemia
      8. Others
    5. Diabetes
    6. Cardiovascular Diseases
    7. Ophthalmic Conditions
    8. Dermatological Diseases
    9. others
  15. asia-pacific biologics MARKET, By end user
    1. overview
    2. Hospitals
    3. Specialty Clinics
    4. Others
  16. asia-pacific biologics MARKET, By distribution channel
    1. overview
    2. hospital pharmacies
    3. retail pharmacies
    4. online Pharmacies
  17. ASIA-PACIFIC biologics market, By Country
    1. Asia-Pacific
      1. China
      2. japan
      3. India
      4. Australia
      5. South Korea
      6. Singapore
      7. Malaysia
      8. INDONESIA
      9. THAILAND
      10. Philippines
      11. VIETNAM
      12. REST OF ASIA-PACIFIC
  18. Asia-Pacific Biologics market: COMPANY landscape
    1. company share analysis: Asia-Pacific
  19. swot analysis
  20. company profile
    1. F. Hoffmann-La Roche Ltd
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    2. pfizer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. MERGER
    3. bristol-meyers squibb company
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent developments
    4. MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. GLAXOSMITHKLINE PLC
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent development
    6. abbvie Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. FDA APPROVAL:
    7. AGC Biologics
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENTS
    8. Bharat Biotech
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENTS
    9. Biocon
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTs
    10. BioDiem
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. Technology Portfolio
      4. RECENT DEVELOPMENT
    11. catalent, inc.
      1. COMPANY SNAPSHOt
      2. revenue analysis
      3. product portfolio
      4. recent development
    12. Celltrion Healthcare Co.,Ltd.
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent development
    13. Johnson & Johnson Services, Inc.
      1. COMPANY SNAPSHOt
      2. revenue analysis
      3. product portfolio
      4. recent development
    14. Biogen
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENT
    15. BeiGene
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    16. chime biologics
      1. COMPANY SNAPSHOt
      2. SERVICE portfolio
      3. recent development
    17. Cipla Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    18. Evotec
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
      5. ACQUISITION
    19. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    20. Innovent
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    21. Intas Pharmaceutical Ltd.
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
    22. Ipsen Pharma
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    23. KM Biologics (A Subsidiary of Meiji Holdings Co., Ltd.)
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENT
    24. nbhl ltd.
      1. COMPANY SNAPSHOt
      2. product portfolio
      3. recent development
    25. Panacea Biotec
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    26. Qilu Pharmaceutical Co., Ltd.
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
    27. SAMSUNG biologics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. ACQUISITION
    28. serum institute of india pvt. ltd.
      1. COMPANY SNAPSHOt
      2. product portfolio
      3. recent developments
    29. Shanghai Henlius Biotech, Inc.
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    30. Teva Pharmaceutical Industries Ltd.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. EXPANSION:
    31. wuxi biologics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. LICENSE:
    32. YL Biologics
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
  21. questionnaire
  22. related reports

표 목록

TABLE 1 pipeline analysis

TABLE 2 REGULATION imposed by several regulatory agencies in different countRIes

TABLE 3 Asia-Pacific Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 4 Asia-Pacific Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 5 Asia-Pacific B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 6 Asia-Pacific Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 7 Asia-Pacific Biologics MARKET, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 8 Asia-Pacific Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 9 Asia-Pacific biologics Market, By Source material, 2020-2029 (USD Million)

TABLE 10 Asia-Pacific biologics Market, By type , 2020-2029 (USD Million)

TABLE 11 Asia-Pacific Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 12 Asia-Pacific Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 13 Asia-Pacific Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 14 Asia-Pacific Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 15 Asia-Pacific Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 16 Asia-Pacific Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 17 Asia-Pacific Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 18 Asia-Pacific Biologics Market, By Distribution Channel, 2020-2029 (USD Million)

TABLE 19 Asia-Pacific biologics market, By COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 China Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 21 China Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 22 China B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 23 China Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 24 China Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 25 China Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 26 China Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 27 China Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 28 China Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 29 China Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 30 China Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 31 China Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 32 China Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 33 China Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 34 China Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 35 China Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 36 Japan Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 37 Japan Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 38 Japan B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 39 Japan Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 40 Japan Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 41 Japan Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 42 Japan Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 43 Japan Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 44 Japan Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 45 Japan Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 46 Japan Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 47 Japan Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 48 Japan Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 49 Japan Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 50 Japan Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 51 Japan Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 52 India Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 53 India Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 54 India B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 55 India Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 56 India Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 57 India Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 58 India Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 59 India Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 60 India Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 61 India Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 62 India Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 63 India Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 64 India Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 65 India Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 66 India Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 67 India Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 68 Australia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 69 Australia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 70 Australia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 71 Australia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 72 Australia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 73 Australia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 74 Australia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 75 Australia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 76 Australia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 77 Australia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 78 Australia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 79 Australia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 80 Australia Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 81 Australia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 82 Australia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 83 Australia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 84 South Korea Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 85 South Korea Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 86 South Korea B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 87 South Korea Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 88 South Korea Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 89 South Korea Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 90 South Korea Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 91 South Korea Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 92 South Korea Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 93 South Korea Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 94 South Korea Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 95 South Korea Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 96 South Korea Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 97 South Korea Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 98 South Korea Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 99 South Korea Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 100 Singapore Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 101 Singapore Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 102 Singapore B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 103 Singapore Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 104 Singapore Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 105 Singapore Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 106 Singapore Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 107 Singapore Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 108 Singapore Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 109 Singapore Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 110 Singapore Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 111 Singapore Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 112 Singapore Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 113 Singapore Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 114 Singapore Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 115 Singapore Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 116 Malaysia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 117 Malaysia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 118 Malaysia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 119 Malaysia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 120 Malaysia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 121 Malaysia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 122 Malaysia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 123 Malaysia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 124 Malaysia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 125 Malaysia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 126 Malaysia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 127 Malaysia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 128 Malaysia  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 129 Malaysia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 130 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 131 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 132 Indonesia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 133 Indonesia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 134 Indonesia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 135 Indonesia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 136 Indonesia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 137 Indonesia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 138 Indonesia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 139 Indonesia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 140 Indonesia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 141 Indonesia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 142 Indonesia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 143 Indonesia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 144 Indonesia  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 145 Indonesia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 146 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 147 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 148 Thailand Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 149 Thailand Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 150 Thailand B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 151 Thailand Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 152 Thailand Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 153 Thailand Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 154 Thailand Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 155 Thailand Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 156 Thailand Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 157 Thailand Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 158 Thailand Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 159 Thailand Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 160 Thailand  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 161 Thailand Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 162 Thailand Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 163 Thailand Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 164 Philippines Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 165 Philippines Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 166 Philippines B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 167 Philippines Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 168 Philippines Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 169 Philippines Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 170 Philippines Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 171 Philippines Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 172 Philippines Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 173 Philippines Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 174 Philippines Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 175 Philippines Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 176 Philippines  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 177 Philippines Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 178 Philippines Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 179 Philippines Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 180 Vietnam Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 181 Vietnam Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 182 Vietnam B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 183 Vietnam Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 184 Vietnam Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 185 Vietnam Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 186 Vietnam Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 187 Vietnam Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 188 Vietnam Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 189 Vietnam Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 190 Vietnam Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 191 Vietnam Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 192 Vietnam  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 193 Vietnam Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 194 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 195 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 196 Rest of Asia-Pacific Biologics Market, BY Class, 2020-2029 (USD Million)

그림 목록

FIGURE 1 Asia-Pacific biologics market: segmentation

FIGURE 2 Asia-Pacific biologics market: data triangulation

FIGURE 3 Asia-Pacific biologics market: DROC ANALYSIS

FIGURE 4 Asia-Pacific biologics market : REGIONAL vs country MARKET ANALYSIS

FIGURE 5 Asia-Pacific biologics market : COMPANY RESEARCH ANALYSIS

FIGURE 6 Asia-Pacific biologics market : multivariate modelling

FIGURE 7 Asia-Pacific biologics market: INTERVIEW DEMOGRAPHICS

FIGURE 8 Asia-Pacific biologics market: DBMR MARKET POSITION GRID

FIGURE 9 Asia-Pacific biologics market: vendor share analysis

FIGURE 10 Asia-Pacific biologics market: application type COVERAGE GRID

FIGURE 11 Asia-Pacific biologics market: SEGMENTATION

FIGURE 12 AN Increase in prevalEnce of chronic diseases such as diabetes and cancers and recent advancements in biologics are expected to drive THE Asia-Pacific biologics market IN THE FORECAST PERIOD of 2022 to 2029

FIGURE 13 tumor necrosis factor-A (TNF) Inhibitors segment is expected to account for the largest share of the Asia-Pacific biologics market in 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITES, AND CHALLENGE OF ASIA-PACIFIC BIOLOGICS MARKET

FIGURE 15 Asia-Pacific biologics market: BY class, 2021

FIGURE 16 ASIA-PACIFIC BIOLOGICS MARKET, BY class, 2020-2029 (USD MILLION)

FIGURE 17 ASIA-PACIFIC BIOLOGICS MARKET: BY class, CAGR (2022-2029)

FIGURE 18 ASIA-PACIFIC BIOLOGICS MARKET: BY class, LIFELINE CURVE

FIGURE 19 Asia-Pacific biologics market: BY route of administration, 2021

FIGURE 20 ASIA-PACIFIC BIOLOGICS MARKET, BY route of administration, 2020-2029 (USD MILLION)

FIGURE 21 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, CAGR (2022-2029)

FIGURE 22 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, LIFELINE CURVE

FIGURE 23 Asia-Pacific biologics market: BY drug classification, 2021

FIGURE 24 ASIA-PACIFIC BIOLOGICS MARKET, BY drug classification, 2020-2029 (USD MILLION)

FIGURE 25 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, CAGR (2022-2029)

FIGURE 26 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, LIFELINE CURVE

FIGURE 27 Asia-Pacific biologics market: BY source material, 2021

FIGURE 28 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, 2020-2029 (USD MILLION)

FIGURE 29 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, CAGR (2022-2029)

FIGURE 30 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2021

FIGURE 32 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2020-2029 (USD MILLION)

FIGURE 33 ASIA-PACIFIC BIOLOGICS MARKET: By type, CAGR (2022-2029)

FIGURE 34 ASIA-PACIFIC BIOLOGICS MARKET: By type, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2021

FIGURE 36 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2020-2029 (USD MILLION)

FIGURE 37 ASIA-PACIFIC BIOLOGICS MARKET: By application, CAGR (2022-2029)

FIGURE 38 ASIA-PACIFIC BIOLOGICS MARKET: By application, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC BIOLOGICS MARKET: By end user , 2021

FIGURE 40 ASIA-PACIFIC BIOLOGICS MARKET: By end USER, 2020-2029 (USD MILLION)

FIGURE 41 ASIA-PACIFIC BIOLOGICS MARKET: By end user , CAGR (2022-2029)

FIGURE 42 ASIA-PACIFIC BIOLOGICS MARKET: By end user , LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2021

FIGURE 44 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2020-2029 (USD MILLION)

FIGURE 45 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, CAGR (2022-2029)

FIGURE 46 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, LIFELINE CURVE

FIGURE 47 Asia-Pacific biologics market: SNAPSHOT (2021)

FIGURE 48 Asia-Pacific biologics market: BY COUNTRY (2021)

FIGURE 49 Asia-Pacific biologics market: BY COUNTRY (2022 & 2029)

FIGURE 50 Asia-Pacific biologics market: BY COUNTRY (2021 & 2029)

FIGURE 51 Asia-Pacific biologics market: BY CLASS (2022-2029)

FIGURE 52 ASIA-PACIFIC Biologics market: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific Biologics Market will be worth USD 141,276.35 million in the forecast period by 2030.
The Asia-Pacific Biologics Market growth rate is 11.5% in the forecast period by 2030.
Changes in lifestyle, Recent advancements in biologics, and the Rising prevalence of chronic diseases such as diabetes and cancers are the growth drivers of the Asia-Pacific Biologics Market.
The class, type, route of administration, application, source material, end user, and distribution channel are the factors on which the Asia-Pacific Biologics Market research is based.
Major companies in the Asia-Pacific Biologics Market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc.

관련 페이지 탐색

Banner